Literature DB >> 25150794

Neonatal euthanasia: lessons from the Groningen Protocol.

A A Eduard Verhagen1.   

Abstract

Decisions about neonatal end-of-life care have been studied intensely over the last 20 years in The Netherlands. Nationwide surveys were done to quantify these decisions, provide details and monitor the effect of guidelines, new regulations and other interventions. One of those interventions was the Groningen Protocol for newborn euthanasia in severely ill newborns, published in 2005. Before publication, an estimated 20 cases of euthanasia per year were performed. After publication, only two cases in five years were reported. Studies suggested that this might be partly caused by the lack of consensus about the dividing line between euthanasia and palliative care. New recommendations about paralytic medication use in dying newborns were issued to increase transparency and to improve reporting of euthanasia. New surveys will be needed to measure the effects of these interventions. This cycle of interventions and measurements seems useful for continuous improvement of end-of-life care in newborns.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ethics; Medical law; Neonatal euthanasia; Neonatal intensive care; Palliative care

Mesh:

Year:  2014        PMID: 25150794     DOI: 10.1016/j.siny.2014.08.002

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  2 in total

Review 1.  Medical assistance in dying: A paediatric perspective.

Authors:  Dawn Davies
Journal:  Paediatr Child Health       Date:  2018-04-12       Impact factor: 2.253

2.  Physicians' attitudes in relation to end-of-life decisions in Neonatal Intensive Care Units: a national multicenter survey.

Authors:  Ilias Chatziioannidis; Zoi Iliodromiti; Theodora Boutsikou; Abraham Pouliakis; Evangelia Giougi; Rozeta Sokou; Takis Vidalis; Theodoros Xanthos; Cuttini Marina; Nicoletta Iacovidou
Journal:  BMC Med Ethics       Date:  2020-11-23       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.